HCA Healthcare price target lowered to $376 from $384 at RBC Capital

RBC Capital analyst Ben Hendrix lowered the firm’s price target on HCA Healthcare (HCA) to $376 from $384 and keeps an Outperform rating on the shares. The stock’s pullback after earnings miss reflects a high bar for quarterly results amid policy overhang, and while the firm remains at Outperform on the name, it is also tempering its price target slightly to reflect continued policy uncertainty, particularly as it relates to Medicaid coverage, exchange subsidies, state directed payments, and tariffs, the analyst tells investors in a research note. Policy aside, RBC is still encouraged by execution on factors within HCA management’s control, the firm adds.